These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18400074)

  • 1. Loss to follow-up in an international, multicentre observational study.
    Mocroft A; Kirk O; Aldins P; Chies A; Blaxhult A; Chentsova N; Vetter N; Dabis F; Gatell J; Lundgren JD;
    HIV Med; 2008 May; 9(5):261-9. PubMed ID: 18400074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence rate and risk factors for loss to follow-up in HIV-infected patients from five French clinical centres in Northern France - January 1997 to December 2006.
    Ndiaye B; Ould-Kaci K; Salleron J; Bataille P; Bonnevie F; Choisy P; Cochonat K; Fontier C; Guerroumi H; Ajana F; Chaud P; Yazdanpanah Y
    Antivir Ther; 2009; 14(4):567-75. PubMed ID: 19578242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study.
    Mocroft A; Monforte Ad; Kirk O; Johnson MA; Friis-Moller N; Banhegyi D; Blaxhult A; Mulcahy F; Gatell JM; Lundgren JD;
    HIV Med; 2004 Nov; 5(6):437-47. PubMed ID: 15544697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study.
    Thierfelder C; Weber R; Elzi L; Furrer H; Cavassini M; Calmy A; Bernasconi E; Gutmann C; Ledergerber B;
    HIV Med; 2012 Feb; 13(2):118-26. PubMed ID: 22107170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata.
    Reekie J; Gatell JM; Yust I; Bakowska E; Rakhmanova A; Losso M; Krasnov M; Francioli P; Kowalska JD; Mocroft A;
    AIDS; 2011 Nov; 25(18):2259-68. PubMed ID: 21918422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of and outcomes in HIV-infected patients who return to care after loss to follow-up.
    Ndiaye B; Ould-Kaci K; Salleron J; Bataille P; Bonnevie F; Cochonat K; Fontier C; Guerroumi H; Yazdanpanah Y
    AIDS; 2009 Aug; 23(13):1786-9. PubMed ID: 19531927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
    Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
    Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk factors associated with lost to follow-up in a Belgian cohort of HIV-infected patients treated with highly active antiretroviral therapy.
    Schepens T; Morreel S; Florence E; Koole O; Colebunders R
    Int J STD AIDS; 2010 Nov; 21(11):765-9. PubMed ID: 21187359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999.
    Mocroft A; Horban A; Clotet B; d'Arminio Monforte A; Bogner JR; Aldins P; Staub T; Antunes F; Katlama C; Lundgren JD;
    HIV Med; 2008 Jan; 9(1):41-6. PubMed ID: 18199171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
    Mocroft A; Ledergerber B; Zilmer K; Kirk O; Hirschel B; Viard JP; Reiss P; Francioli P; Lazzarin A; Machala L; Phillips AN; Lundgren JD;
    AIDS; 2007 Sep; 21(14):1867-75. PubMed ID: 17721094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
    Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
    AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.
    Mussini C; Manzardo C; Johnson M; Monforte Ad; Uberti-Foppa C; Antinori A; Gill MJ; Sighinolfi L; Borghi V; Lazzarin A; Miró JM; Sabin C;
    AIDS; 2008 Nov; 22(18):2461-9. PubMed ID: 19005269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study.
    Sogaard OS; Lohse N; Gerstoft J; Kronborg G; Ostergaard L; Pedersen C; Pedersen G; Sørensen HT; Obel N
    Clin Infect Dis; 2008 Nov; 47(10):1345-53. PubMed ID: 18834317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
    El Amari EB; Toutous-Trellu L; Gayet-Ageron A; Baumann M; Cathomas G; Steffen I; Erb P; Mueller NJ; Furrer H; Cavassini M; Vernazza P; Hirsch HH; Bernasconi E; Hirschel B;
    AIDS; 2008 May; 22(9):1019-28. PubMed ID: 18520345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.
    Khanna N; Elzi L; Mueller NJ; Garzoni C; Cavassini M; Fux CA; Vernazza P; Bernasconi E; Battegay M; Hirsch HH;
    Clin Infect Dis; 2009 May; 48(10):1459-66. PubMed ID: 19348592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression.
    Smith CJ; Phillips AN; Dauer B; Johnson MA; Lampe FC; Youle MS; Tyrer M; Staszewski S
    HIV Med; 2009 Jan; 10(1):19-27. PubMed ID: 19018880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-infected patients with a large thymus maintain higher CD4 counts in a 5-year follow-up study of patients treated with highly active antiretroviral therapy.
    Kolte L; Ryder LP; Albrecht-Beste E; Jensen FK; Nielsen SD
    Scand J Immunol; 2009 Dec; 70(6):608-13. PubMed ID: 19906203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.